GPP
Great Point Partners Portfolio holdings
AUM
$154M
1-Year Return
2.36%
This Quarter Return
-11.32%
1 Year Return
-2.36%
3 Year Return
+169.3%
5 Year Return
+292.82%
10 Year Return
+3,519.88%
AUM
$212M
AUM Growth
-$119M
(-36%)
Cap. Flow
-$58.7M
Cap. Flow
% of AUM
-27.64%
Top 10 Holdings %
Top 10 Hldgs %
61.58%
Holding
33
New
4
Increased
5
Reduced
13
Closed
7
Top Buys
| 1 |
Xenon Pharmaceuticals
XENE
|
$9.61M |
| 2 |
Ionis Pharmaceuticals
IONS
|
$8.74M |
| 3 |
UPB
Upstream Bio, Inc. Common Stock
UPB
|
$4.93M |
| 4 |
KalVista Pharmaceuticals
KALV
|
$4.13M |
| 5 |
MREO
Mereo BioPharma
MREO
|
$4.03M |
Top Sells
| 1 |
Neurogene
NGNE
|
$12.8M |
| 2 |
Olema Pharmaceuticals
OLMA
|
$11.9M |
| 3 |
Pliant Therapeutics
PLRX
|
$11.3M |
| 4 |
Arcellx
ACLX
|
$8.35M |
| 5 |
Outlook Therapeutics
OTLK
|
$6.9M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
UroGen Pharma
URGN
$870M
| $2M | 0.94% |
187,843
-570,943
| -75% | -$6.08M |
|
|
27
Arcellx
ACLX
$4B
| – | – |
-100,000
| Closed | -$8.35M |
|
|
28
Olema Pharmaceuticals
OLMA
$436M
| – | – |
-1,000,000
| Closed | -$11.9M |
|
|
29
Outlook Therapeutics
OTLK
$39.5M
| – | – |
-1,293,028
| Closed | -$6.9M |
|
30
Cartesian Therapeutics
RNAC
$260M
| – | – |
-200,000
| Closed | -$3.22M |
|
31
TScan Therapeutics
TCRX
$107M
| – | – |
-1,016,375
| Closed | -$5.06M |
|
32
VistaGen Therapeutics
VTGN
$111M
| – | – |
-674,075
| Closed | -$2.03M |
|
|
CLYM
33
Climb Bio, Inc. Common Stock
CLYM
$158M
| – | – |
-248,168
| Closed | -$1.26M |
|